Roivant Executive and Leadership Team

Hao Xing, the Chief of Staff & Chief Executive Officer, Office at Roivant, directs the internal alignment of corporate strategy and executive operations. Managing the daily functions of the executive office, the Chief of Staff & Chief Executive Officer, Office ensures that organizational priorities remain synchronized with the broader mission of advancing late-stage drug candidates. This leadership role involves coordinating cross-functional initiatives to optimize resource allocation across the entire enterprise. By streamlining communication between departments, Hao Xing facilitates rapid decision-making processes that support the company's tech-enabled healthcare model. The Chief of Staff & Chief Executive Officer, Office also monitors performance metrics to ensure that operational goals align with long-term growth objectives. Through rigorous oversight of internal workflows, the executive maintains high standards of efficiency, ultimately driving the successful execution of complex pharmaceutical development projects across global markets.

Stephanie Griffin, the Chief Operating Officer, Roivant Platforms at Roivant, manages the operational execution of the company's diverse platform initiatives. Overseeing the scaling of internal processes, the Chief Operating Officer, Roivant Platforms ensures that each platform maintains the agility required to advance promising drug candidates through clinical milestones. This leadership role involves optimizing supply chain logistics and operational workflows to maximize productivity across North American and international research hubs. By fostering collaboration between platform teams and external partners, Stephanie Griffin drives the successful transition of research projects into viable healthcare solutions. The Chief Operating Officer, Roivant Platforms also monitors operational risks and implements mitigation strategies to ensure project continuity. Through the application of lean management principles, the executive enhances organizational performance, directly contributing to the company's ability to deliver innovative medical technologies to patients worldwide.

Ian Rosenblum, the Chief Information Officer at Roivant, architects the digital infrastructure necessary to support advanced healthcare technology initiatives. Overseeing the integration of data analytics and secure information systems, the Chief Information Officer ensures that research teams possess the computational tools required for late-stage drug development. This role involves managing cybersecurity protocols and cloud-based platforms that house critical clinical data. By implementing scalable software solutions, Ian Rosenblum enables seamless collaboration across international research sites, enhancing the speed of data-driven insights. The Chief Information Officer also collaborates with other C-suite leaders to align technological investments with the company's overarching R&D strategy. Through the deployment of robust digital frameworks, the executive supports the continuous improvement of healthcare delivery systems, ensuring that the organization maintains a competitive edge in the rapidly evolving pharmaceutical technology sector.

Deya Corzo, the Chief Medical Officer, -Residence at Roivant, directs the clinical strategy and medical oversight for late-stage drug development programs. Managing the design and execution of clinical trials, the Chief Medical Officer, -Residence ensures that all research activities adhere to rigorous safety and regulatory standards. This role involves interpreting complex clinical data to guide the progression of therapeutic candidates toward market approval. By collaborating with regulatory bodies and internal research teams, Deya Corzo facilitates the efficient advancement of medical innovations. The Chief Medical Officer, -Residence also provides critical medical expertise to support the evaluation of new healthcare technologies, ensuring that clinical outcomes remain the primary focus of the development pipeline. Through the leadership of medical affairs, the executive secures the scientific integrity of the company's portfolio, ultimately improving patient access to life-changing treatments across global healthcare markets.